Brokerages Set Climb Bio, Inc. (NASDAQ:CLYM) Price Target at $21.73

Climb Bio, Inc. (NASDAQ:CLYM) has been given a consensus recommendation of “Buy” by the fourteen analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, ten have given a buy rating and three have given a strong buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $21.7273.

Several equities analysts have commented on the stock. Wall Street Zen upgraded shares of Climb Bio from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Climb Bio in a research report on Monday, April 20th. Guggenheim started coverage on shares of Climb Bio in a research report on Monday, June 8th. They set a “buy” rating and a $35.00 price objective for the company. Mizuho began coverage on Climb Bio in a research note on Wednesday, April 15th. They set an “outperform” rating and a $18.00 target price for the company. Finally, B. Riley Financial began coverage on shares of Climb Bio in a research note on Tuesday, March 24th. They issued a “buy” rating and a $26.00 price objective for the company.

Institutional Trading of Climb Bio

A number of institutional investors and hedge funds have recently made changes to their positions in CLYM. Seven Fleet Capital Management LP purchased a new position in Climb Bio in the 4th quarter worth approximately $306,000. ArchPoint Investors bought a new stake in Climb Bio in the fourth quarter valued at about $486,000. 683 Capital Management LLC bought a new stake in shares of Climb Bio in the 4th quarter valued at approximately $807,000. Peapod Lane Capital LLC raised its holdings in shares of Climb Bio by 0.7% during the fourth quarter. Peapod Lane Capital LLC now owns 565,992 shares of the company’s stock worth $2,264,000 after purchasing an additional 4,126 shares during the period. Finally, The Manufacturers Life Insurance Company raised its stake in Climb Bio by 261.5% during the fourth quarter. The Manufacturers Life Insurance Company now owns 140,617 shares of the company’s stock worth $567,000 after acquiring an additional 101,717 shares during the period. 69.76% of the stock is currently owned by institutional investors and hedge funds.

Climb Bio Stock Performance

Shares of NASDAQ:CLYM opened at $14.00 on Monday. Climb Bio has a 12-month low of $1.32 and a 12-month high of $14.41. The company has a market capitalization of $801.64 million, a price-to-earnings ratio of -17.95 and a beta of 0.07. The business has a 50-day moving average price of $11.67 and a 200 day moving average price of $8.14.

Climb Bio (NASDAQ:CLYM) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.06. As a group, equities research analysts predict that Climb Bio will post -0.87 earnings per share for the current fiscal year.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.